Martingale Asset Management L P Buys Shares of 18,780 Lantheus Holdings, Inc. $LNTH

Key Points

• Martingale Asset Management L P has acquired a new stake in Lantheus Holdings, Inc., purchasing 18,780 shares valued at approximately $1,833,000 in the first quarter.
• Insider trading activity includes Director Mary Anne Heino selling 26,066 shares and Farallon Partners L.L.C. selling 3,365,000 shares, indicating significant shifts in insider ownership.
• Lantheus reported a quarterly EPS of $1.57, missing estimates, with revenue of $378.05 million, which is a 4.1% decline compared to the same quarter last year.

Martingale Asset Management L P bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 18,780 shares of the medical equipment provider's stock, valued at approximately $1,833,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Signaturefd LLC boosted its position in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 116 shares in the last quarter. Hughes Financial Services LLC purchased a new position in Lantheus during the first quarter valued at $81,000. UMB Bank n.a. boosted its holdings in shares of Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after buying an additional 381 shares in the last quarter. Blue Trust Inc. grew its position in shares of Lantheus by 117.7% in the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock worth $114,000 after buying an additional 633 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Lantheus by 29.3% in the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock worth $128,000 after buying an additional 298 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on LNTH shares. JMP Securities dropped their price objective on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. William Blair reissued a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. Mizuho cut their price target on Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, August 7th. Truist Financial set a $63.00 price objective on Lantheus and gave the company a "hold" rating in a research note on Monday, August 11th. Finally, Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Lantheus presently has a consensus rating of "Moderate Buy" and a consensus target price of $105.50.

Insider Buying and Selling

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,838,066 shares of company stock worth $384,430,031. 2.00% of the stock is owned by insiders.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded up $1.18 during midday trading on Wednesday, reaching $56.84. 692,361 shares of the company's stock traded hands, compared to its average volume of 1,204,992. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $118.21. The company has a market cap of $3.86 billion, a price-to-earnings ratio of 15.12 and a beta of 0.14. The stock has a 50 day moving average of $70.60 and a 200 day moving average of $83.77.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). The business had revenue of $378.05 million during the quarter, compared to analysts' expectations of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.Lantheus's quarterly revenue was down 4.1% compared to the same quarter last year. During the same period last year, the firm posted $1.80 EPS. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.